Selected research
Industry Research
Therapeutic Radioligands Drug Industry Research Report 2026
Market perspective
The global Therapeutic Radioligands Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Therapeutic Radioligands Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Therapeutic Radioligands Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Therapeutic Radioligands Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Therapeutic Radioligands Drug include Novartis, Mundipharma, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med and Nordic Nanovector, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Therapeutic Radioligands Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Therapeutic Radioligands Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Therapeutic Radioligands Drug Market by Company
Novartis
Mundipharma
Bayer
Y-mAbs Therapeutics
Telix Pharmaceuticals
RadioMedix
Philogen
Orano Med
Nordic Nanovector
Lantheus
Gilead Sciences
Fusion Pharmaceuticals
Curium Pharmaceuticals
Curasight
Clarity Pharmaceuticals
China Isotope & Radiation
Aurobindo Pharma
Actinium Pharmaceuticals
Therapeutic Radioligands Drug Segment by Type
Beta-emitting
Targeted Alpha Therapy
Therapeutic Radioligands Drug Segment by Application
Solid Tumor
Non Hodgkin Lymphoma
Therapeutic Radioligands Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Radioligands Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Radioligands Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Radioligands Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Therapeutic Radioligands Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Beta-emitting
- Targeted Alpha Therapy
Applications
- Solid Tumor
- Non Hodgkin Lymphoma
Companies covered
- Novartis
- Mundipharma
- Bayer
- Y-mAbs Therapeutics
- Telix Pharmaceuticals
- RadioMedix
- Philogen
- Orano Med
- Nordic Nanovector
- Lantheus
- Gilead Sciences
- Fusion Pharmaceuticals
- Curium Pharmaceuticals
- Curasight
- Clarity Pharmaceuticals
- China Isotope & Radiation
- Aurobindo Pharma
- Actinium Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Therapeutic Radioligands Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Beta-emitting
- 2.2.3 Targeted Alpha Therapy
- 2.3 Therapeutic Radioligands Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Solid Tumor
- 2.3.3 Non Hodgkin Lymphoma
- 2.4 Assumptions and Limitations
3 Therapeutic Radioligands Drug Breakdown Data by Type
- 3.1 Global Therapeutic Radioligands Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Therapeutic Radioligands Drug Forecasted Market Size by Type (2027-2032)
4 Therapeutic Radioligands Drug Breakdown Data by Application
- 4.1 Global Therapeutic Radioligands Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Therapeutic Radioligands Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Therapeutic Radioligands Drug Market Perspective (2021-2032)
- 5.2 Global Therapeutic Radioligands Drug Growth Trends by Region
- 5.2.1 Global Therapeutic Radioligands Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Therapeutic Radioligands Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Therapeutic Radioligands Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Therapeutic Radioligands Drug Market Dynamics
- 5.3.1 Therapeutic Radioligands Drug Industry Trends
- 5.3.2 Therapeutic Radioligands Drug Market Drivers
- 5.3.3 Therapeutic Radioligands Drug Market Challenges
- 5.3.4 Therapeutic Radioligands Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Therapeutic Radioligands Drug Players by Revenue
- 6.1.1 Global Top Therapeutic Radioligands Drug Players by Revenue (2021-2026)
- 6.1.2 Global Therapeutic Radioligands Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Therapeutic Radioligands Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Therapeutic Radioligands Drug Head Office and Area Served
- 6.4 Global Therapeutic Radioligands Drug Players, Product Type & Application
- 6.5 Global Therapeutic Radioligands Drug Manufacturers Established Date
- 6.6 Global Therapeutic Radioligands Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Therapeutic Radioligands Drug Market Size (2021-2032)
- 7.2 North America Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Therapeutic Radioligands Drug Market Size by Country (2021-2026)
- 7.4 North America Therapeutic Radioligands Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Therapeutic Radioligands Drug Market Size (2021-2032)
- 8.2 Europe Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Therapeutic Radioligands Drug Market Size by Country (2021-2026)
- 8.4 Europe Therapeutic Radioligands Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Therapeutic Radioligands Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Therapeutic Radioligands Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Therapeutic Radioligands Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Therapeutic Radioligands Drug Market Size (2021-2032)
- 10.2 South America Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Therapeutic Radioligands Drug Market Size by Country (2021-2026)
- 10.4 South America Therapeutic Radioligands Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Therapeutic Radioligands Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis
- 12.1.1 Novartis Company Information
- 12.1.2 Novartis Business Overview
- 12.1.3 Novartis Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.1.4 Novartis Therapeutic Radioligands Drug Product Portfolio
- 12.1.5 Novartis Recent Developments
- 12.2 Mundipharma
- 12.2.1 Mundipharma Company Information
- 12.2.2 Mundipharma Business Overview
- 12.2.3 Mundipharma Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.2.4 Mundipharma Therapeutic Radioligands Drug Product Portfolio
- 12.2.5 Mundipharma Recent Developments
- 12.3 Bayer
- 12.3.1 Bayer Company Information
- 12.3.2 Bayer Business Overview
- 12.3.3 Bayer Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.3.4 Bayer Therapeutic Radioligands Drug Product Portfolio
- 12.3.5 Bayer Recent Developments
- 12.4 Y-mAbs Therapeutics
- 12.4.1 Y-mAbs Therapeutics Company Information
- 12.4.2 Y-mAbs Therapeutics Business Overview
- 12.4.3 Y-mAbs Therapeutics Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.4.4 Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Portfolio
- 12.4.5 Y-mAbs Therapeutics Recent Developments
- 12.5 Telix Pharmaceuticals
- 12.5.1 Telix Pharmaceuticals Company Information
- 12.5.2 Telix Pharmaceuticals Business Overview
- 12.5.3 Telix Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.5.4 Telix Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
- 12.5.5 Telix Pharmaceuticals Recent Developments
- 12.6 RadioMedix
- 12.6.1 RadioMedix Company Information
- 12.6.2 RadioMedix Business Overview
- 12.6.3 RadioMedix Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.6.4 RadioMedix Therapeutic Radioligands Drug Product Portfolio
- 12.6.5 RadioMedix Recent Developments
- 12.7 Philogen
- 12.7.1 Philogen Company Information
- 12.7.2 Philogen Business Overview
- 12.7.3 Philogen Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.7.4 Philogen Therapeutic Radioligands Drug Product Portfolio
- 12.7.5 Philogen Recent Developments
- 12.8 Orano Med
- 12.8.1 Orano Med Company Information
- 12.8.2 Orano Med Business Overview
- 12.8.3 Orano Med Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.8.4 Orano Med Therapeutic Radioligands Drug Product Portfolio
- 12.8.5 Orano Med Recent Developments
- 12.9 Nordic Nanovector
- 12.9.1 Nordic Nanovector Company Information
- 12.9.2 Nordic Nanovector Business Overview
- 12.9.3 Nordic Nanovector Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.9.4 Nordic Nanovector Therapeutic Radioligands Drug Product Portfolio
- 12.9.5 Nordic Nanovector Recent Developments
- 12.10 Lantheus
- 12.10.1 Lantheus Company Information
- 12.10.2 Lantheus Business Overview
- 12.10.3 Lantheus Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.10.4 Lantheus Therapeutic Radioligands Drug Product Portfolio
- 12.10.5 Lantheus Recent Developments
- 12.11 Gilead Sciences
- 12.11.1 Gilead Sciences Company Information
- 12.11.2 Gilead Sciences Business Overview
- 12.11.3 Gilead Sciences Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.11.4 Gilead Sciences Therapeutic Radioligands Drug Product Portfolio
- 12.11.5 Gilead Sciences Recent Developments
- 12.12 Fusion Pharmaceuticals
- 12.12.1 Fusion Pharmaceuticals Company Information
- 12.12.2 Fusion Pharmaceuticals Business Overview
- 12.12.3 Fusion Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.12.4 Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
- 12.12.5 Fusion Pharmaceuticals Recent Developments
- 12.13 Curium Pharmaceuticals
- 12.13.1 Curium Pharmaceuticals Company Information
- 12.13.2 Curium Pharmaceuticals Business Overview
- 12.13.3 Curium Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.13.4 Curium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
- 12.13.5 Curium Pharmaceuticals Recent Developments
- 12.14 Curasight
- 12.14.1 Curasight Company Information
- 12.14.2 Curasight Business Overview
- 12.14.3 Curasight Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.14.4 Curasight Therapeutic Radioligands Drug Product Portfolio
- 12.14.5 Curasight Recent Developments
- 12.15 Clarity Pharmaceuticals
- 12.15.1 Clarity Pharmaceuticals Company Information
- 12.15.2 Clarity Pharmaceuticals Business Overview
- 12.15.3 Clarity Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.15.4 Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
- 12.15.5 Clarity Pharmaceuticals Recent Developments
- 12.16 China Isotope & Radiation
- 12.16.1 China Isotope & Radiation Company Information
- 12.16.2 China Isotope & Radiation Business Overview
- 12.16.3 China Isotope & Radiation Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.16.4 China Isotope & Radiation Therapeutic Radioligands Drug Product Portfolio
- 12.16.5 China Isotope & Radiation Recent Developments
- 12.17 Aurobindo Pharma
- 12.17.1 Aurobindo Pharma Company Information
- 12.17.2 Aurobindo Pharma Business Overview
- 12.17.3 Aurobindo Pharma Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.17.4 Aurobindo Pharma Therapeutic Radioligands Drug Product Portfolio
- 12.17.5 Aurobindo Pharma Recent Developments
- 12.18 Actinium Pharmaceuticals
- 12.18.1 Actinium Pharmaceuticals Company Information
- 12.18.2 Actinium Pharmaceuticals Business Overview
- 12.18.3 Actinium Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026)
- 12.18.4 Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
- 12.18.5 Actinium Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst